Letter to the editor of the Brit J Clin Pharmacol on Hartjes et al. 2025 https://doi.org/10.1002/bcp.70176

Documenti analoghi

• Letter to the editor of the Brit J Clin Pharmacol on Heuberger et al. 2025 https://doi.org/10.1002/bcp.70090
  di: Markus Hinder, et al.
  Pubblicazione: (2025)
• Letter to the Editor of the British Journal of Clinical Pharmacology Re: van Iersel et al. (2026)—Why do healthy volunteers participate in clinical trials? doi: https://doi.org/10.1002/bcp.70499
  di: Kasra Shakeri‐Nejad, et al.
  Pubblicazione: (2026)
• Manufacturer‐documented infrared interference from SSRIs: A confound in breast milk fat and pharmacokinetic studies re: (1) Monfort A., et al. Br J Clin Pharmacol. 2024;90(11):2849–2860. (2) Weisskopf E, et al. Br J Clin Pharmacol. 2020;86:1642–1653
  di: Kaytlin Krutsch
  Pubblicazione: (2026)
• Letter to the editor: Personalized antihypertensive treatment—The role of body fat indices beyond body mass index
  di: Christina Antza, et al.
  Pubblicazione: (2024)
• Letter to the editor concerning the article: ‘The impacts of undetected nonadherence in phase II, III and post‐marketing clinical trials: An overview’
  di: Tamás Ágh, et al.
  Pubblicazione: (2025)